Eli Lilly's QWINT-2 And QWINT-4 Phase 3 Trials Of Once-weekly Insulin Efsitora In Type 2 Diabetes Patients Using Insulin For First Time And Require Multiple Daily Injections, Efsitora Showed Non-Inferior A1C Reduction Vs. Most Commonly Used Daily Insulin
Eli Lilly's QWINT-2 And QWINT-4 Phase 3 Trials Of Once-weekly Insulin Efsitora In Type 2 Diabetes Patients Using Insulin For First Time And Require Multiple Daily Injections, Efsitora Showed Non-Inferior A1C Reduction Vs. Most Commonly Used Daily Insulin
禮來公司的 QWINT-2 和 QWINT-4 三期試驗，針對首次使用胰島素且需要每天多次注射的 2 型糖尿病患者每週一次的胰島素 Efsitora，Efsitora 的A1C降低幅度與最常用的每日胰島素
- Efsitora met the primary endpoint in both QWINT-2 and QWINT-4 with once-a-week dosing regimen for people living with type 2 diabetes
- Efsitora was equally safe and effective among adults naïve to insulin therapy currently using and not using GLP-1 receptor agonists
- Efsitora 通過針對 2 型糖尿病患者每週一次的給藥方案，達到 QWINT-2 和 QWINT-4 的主要終點
- 對於目前使用和不使用 GLP-1 受體激動劑的胰島素治療不熟練的成年人來說，Efsitora 同樣安全有效
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。